Jung Chan-Young, Kim Hyung Woo, Ahn Sang Hoon, Kim Seung Up, Kim Beom Seok
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
Clin Gastroenterol Hepatol. 2022 Apr;20(4):956-958.e2. doi: 10.1016/j.cgh.2021.05.032. Epub 2021 May 21.
Of the antiviral agents currently available to patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are 2 of 3 first-line agents. Given the well-known renal and bone toxicity associated with TDF, major international hepatitis B virus treatment guidelines recommend ETV over TDF in patients with predisposing factors to kidney function decline. However, as evidenced by recent studies, nephrotoxicity of antiviral agents is still an issue under debate. Therefore, we investigated the differences in the risk of kidney function decline in patients with treatment-naive CHB who were treated with ETV or TDF.
在目前可供慢性乙型肝炎（CHB）患者使用的抗病毒药物中，恩替卡韦（ETV）和替诺福韦酯（TDF）是三种一线药物中的两种。鉴于TDF存在众所周知的肾脏和骨骼毒性，主要的国际乙型肝炎病毒治疗指南建议，对于有肾功能下降易感因素的患者，优先使用ETV而非TDF。然而，最近的研究表明，抗病毒药物的肾毒性仍是一个存在争议的问题。因此，我们调查了初治CHB患者接受ETV或TDF治疗后肾功能下降风险的差异。
